Company Description
City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules.
The company develops RNAi-based medicines using engineered small interfering RNAs (siRNAs) and is building a pipeline of therapeutics targeting diseases across multiple therapeutic areas, including ophthalmologic conditions such as retinal diseases and geographic atrophy.
It designs and engineers RNAi trigger molecules, such as smaller size, novel cleavage mechanisms, and tailored targeting ligands to enhance potency, specificity, and delivery to various tissue types.
Its products includes CITY-FXI, is a city-engineered n-acetylgalactosamine -conjugated small interfering RNA therapeutic targeting factor XI; CITY-RBP4, is a city-engineered GalNAc-conjugated siRNA therapeutic, in development for the treatment of Stargardt disease; CITY-TFR2, is a city-engineered GalNAc-conjugated siRNA therapeutic candidate in development for anemia of chronic disease; The company advances these therapeutics from research through clinical and commercial development stages and engages in strategic collaborations to co-develop RNAi clinical candidates.
It has a strategic collaborations with Bausch + Lomb Ireland Limited and Biogen MA Inc. to advance extrahepatic RNAi therapeutics for diseases of the eye and the central nervous system.
The company serves clients in the pharmaceutical, biotechnology, and life sciences industries and collaborates with organizations in the ophthalmology sector.
The company was incorporated in 2023 and is based in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2023 |
| IPO Date | Oct 16, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 75 |
| CEO | Andrew Orth |
Contact Details
Address: 399 Binney Street Cambridge, Massachusetts 02142 United States | |
| Phone | 857 357 2024 |
| Website | citytx.com |
Stock Details
| Ticker Symbol | CTY |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 2143850 |
| Employer ID | 93-2762122 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Andrew (Andy) Orth, M.B.A. | President, Chief Executive Officer and Director |
| Keith Regnante, M.B.A. | Chief Financial Officer |
| Baisong Mei, M.D., Ph.D. | Chief Medical Officer |
| Tracy Zimmermann, Ph.D. | Chief Scientific Officer |
| Sebastian Trousil, Ph.D. | Chief Operating Officer |
| John Maraganore, Ph.D. | Executive Chair |
| Barry Greene | Director |
| Robert Nelsen, M.B.A. | Director |
| Saraswathy (Sara) V. Nochur, Ph.D. | Director |
| Ron Philip | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 16, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Oct 16, 2026 | 424B4 | Prospectus |
| Oct 15, 2026 | EFFECT | Notice of Effectiveness |
| Oct 15, 2026 | S-1MEF | Registration adding securities to prior Form S-1 registration |
| Oct 15, 2026 | CERT | Certification by an exchange approving securities for listing |
| Oct 13, 2026 | 8-A12B | Registration of securities |
| Oct 9, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Sep 24, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Aug 24, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jul 15, 2026 | DRS | [Cover] Draft Registration Statement |